iECURE, a Philadelphia, PA-based gene modifying firm, raised $65m in Collection A-1 funding.
The spherical was led by Novo Holdings A/S and LYFE Capital with participation from Versant Ventures and OrbiMed Advisors. As a part of the Collection A-1 financing, Ray Camahort, Ph.D., Companion at Novo Ventures and Derek Yuan, Ph.D., Managing Director at LYFE Capital will be a part of iECURE’s Board of Administrators. Moreover, Tal Zaks, M.D., Ph.D., has been appointed to iECURE’s board as OrbiMed’s new consultant on the Board of Administrators. Stephen Squinto, Ph.D., will proceed to serve on the Board of Administrators as an unbiased member.
Led by CEO Joseph Truitt, iECURE is a gene modifying firm targeted on creating therapies that make the most of mutation-agnostic in vivo gene insertion, or knock-in, modifying for the therapy of liver issues with vital unmet want.
The corporate intends to make use of the funds to execute all of the duties vital to start scientific growth of what may very well be the mutation-agnostic in vivo gene insertion therapeutic program. The funding is predicted to allow completion of pre-IND actions, scientific trial initiation, and receipt of scientific knowledge from the Section 1/2 scientific trial of iECURE’s lead investigational product for Ornithine Transcarbamylase (OTC) deficiency in addition to pre-IND actions for Citrullinemia Sort 1 (CTLN1).
This financing, coupled with the $50m raised within the prior Collection A financing introduced in September 2021, will convey the corporate’s complete funds raised to $115m.